We are entering an exciting time, with the concept of precision or individualized medicine directing clinical diagnostics, selection criteria for targeted clinical trials, and patient-tailored therapeutic intervention strategies. Indeed, technological advances have elevated genetic studies and opened an opportunity to gain insight into the genome that could not have been envisioned a decade ago. As we await the arrival of the affordable whole-genome sequence, current costs can run just over the goal of $1000 per genome, investigators have used the capture-sequence approach of exome sequencing in the mission of identifying actionable coding variants and thus the genes involved in disease pathogenesis.